Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Esperion Aims Low On Price For Cholesterol Drug Bempedoic Acid

Executive Summary

Esperion is emphasizing the low list and net price of its oral bempedoic acid for cholesterol reduction, relative to the injectable PCSCK9 inhibitors, but still significantly higher than other oral cholesterol-lowering drugs.

Advertisement

Related Content

Esperion Expects Preferred Formulary Placement For Oral Cholesterol Drug Bempedoic Acid
Deaths In Esperion's Long-Term Bempedoic Acid Trial Spur Fears Of Commercial Delay
PCSK9 Turning Point? Sanofi/Regeneron Dangle Lower Price Carrot For Praluent
Praluent Pricing: Collaboration With ICER Sets A New Standard
Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha
Can Cholesterol Drug Sponsors Make The Case For Statin Intolerance?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123399

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel